|
1
|
Finegold JA, Asaria P and Francis DP:
Mortality from ischaemic heart disease by country, region, and age:
Statistics from World Health Organisation and United Nations. Int J
Cardiol. 168:934–945. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Tabei SM, Senemar S, Saffari B, Ahmadi Z
and Haqparast S: Non-modifiable factors of coronary artery stenosis
in late onset patients with coronary artery disease in Southern
Iranian population. J Cardiovasc Thorac Res. 6:51–55.
2014.PubMed/NCBI
|
|
3
|
Cannon CP: Cardiovascular disease and
modifiable cardiometabolic risk factors. Clin Cornerstone. 8:11–28.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Grundy SM: Metabolic syndrome: A multiplex
cardiovascular risk factor. J Clin Endocrinol Metab. 92:399–404.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Consultation WHO Definition, diagnosis and
classification of diabetes mellitus and its complications. World
Health Organization. Geneva, Switzerland: 31–33. 1999.
|
|
6
|
Balkau B and Charles MA: European Group
for the Study of Insulin Resistance (EGIR): Comment on the
provisional report from the WHO consultation. Diabet Med.
16:442–443. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Expert Panel on Detection, Evaluation, and
Treatment of High Blood Cholesterol in Adults: Executive Summary of
The Third Report of The National Cholesterol Education Program
(NCEP) Expert Panel on Detection, Evaluation, And Treatment of High
Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA.
285:2486–2497. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
International Diabetes Federation: The IDF
Consensus Worldwide Definition of the Metabolic Syndrome.
International Diabetes Federation (Brussels, Belgium). 2006.
|
|
9
|
Ge Y and Wang TJ: Identifying novel
biomarkers for cardiovascular disease risk prediction. J Intern
Med. 272:430–439. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Khot UN, Khot MB, Bajzer CT, Sapp SK,
Ohman EM, Brener SJ, Ellis SG, Lincoff AM and Topol EJ: Prevalence
of conventional risk factors in patients with coronary heart
disease. JAMA. 290:898–904. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Montgomery JE and Brown JR: Metabolic
biomarkers for predicting cardiovascular disease. Vasc Health Risk
Manag. 9:37–45. 2013.PubMed/NCBI
|
|
12
|
van Holten TC, Waanders LF, de Groot PG,
Vissers J, Hoefer IE, Pasterkamp G, Prins MW and Roest M:
Circulating biomarkers for predicting cardiovascular disease risk;
a systematic review and comprehensive overview of meta-analyses.
PLoS One. 8:e620802013. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Libby P, Geng YJ, Aikawa M, Schoenbeck U,
Mach F, Clinton SK, Sukhova GK and Lee RT: Macrophages and
atherosclerotic plaque stability. Curr Opin Lipidol. 7:330–335.
1996. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Handberg A, Levin K, Højlund K and
Beck-Nielsen H: Identification of the oxidized low-density
lipoprotein scavenger receptor CD36 in plasma: A novel marker of
insulin resistance. Circulation. 114:1169–1176. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Park YM: CD36, a scavenger receptor
implicated in atherosclerosis. Exp Mol Med. 46:e992014. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Bonen A, Campbell SE, Benton CR, Chabowski
A, Coort SL, Han XX, Koonen DP, Glatz JF and Luiken JJ: Regulation
of fatty acid transport by fatty acid translocase/CD36. Proc Nutr
Soc. 63:245–249. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Alkhatatbeh MJ, Enjeti AK, Acharya S,
Thorne RF and Lincz LF: The origin of circulating CD36 in type 2
diabetes. Nutr Diabetes. 3:e592013. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Glintborg D, Højlund K, Andersen M,
Henriksen JE, Beck-Nielsen H and Handberg A: Soluble CD36 and risk
markers of insulin resistance and atherosclerosis are elevated in
polycystic ovary syndrome and significantly reduced during
pioglitazone treatment. Diabetes Care. 31:328–334. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Handberg A, Skjelland M, Michelsen AE,
Sagen EL, Krohg-Sørensen K, Russell D, Dahl A, Ueland T, Oie E,
Aukrust P, et al: Soluble CD36 in plasma is increased in patients
with symptomatic atherosclerotic carotid plaques and is related to
plaque instability. Stroke. 39:3092–3095. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Khader Y, Batieha A, Jaddou H, El-Khateeb
M and Ajlouni K: Metabolic Syndrome and Its Individual Components
among Jordanian Children and Adolescents. Int J Pediatr Endocrinol.
2010:3161702010. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
American Diabetes Association: Diagnosis
and classification of diabetes mellitus. Diabetes Care. 33(Suppl
1): S62–S69. 2010.PubMed/NCBI
|
|
22
|
Ramos-Arellano LE, Muñoz-Valle JF, De la
Cruz-Mosso U, Salgado-Bernabé AB, Castro-Alarcón N and Parra-Rojas
I: Circulating CD36 and oxLDL levels are associated with
cardiovascular risk factors in young subjects. BMC Cardiovasc
Disord. 14:542014. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Wu S, Yang D, Wei H, Wang B, Huang J, Li
H, Shima M, Deng F and Guo X: Association of chemical constituents
and pollution sources of ambient fine particulate air pollution and
biomarkers of oxidative stress associated with atherosclerosis: A
panel study among young adults in Beijing, China. Chemosphere.
135:347–353. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Krzystolik A, Dziedziejko V, Safranow K,
Kurzawski G, Rać M, Sagasz-Tysiewicz D, Poncyljusz W, Jakubowska K,
Chlubek D and Rać ME: Is plasma soluble CD36 associated with
cardiovascular risk factors in early onset coronary artery disease
patients? Scand J Clin Lab Invest. 75:398–406. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Himoto T, Tani J, Miyoshi H, Morishita A,
Yoneyama H, Kurokohchi K, Inukai M, Masugata H, Goda F, Senda S, et
al: Investigation of the factors associated with circulating
soluble CD36 levels in patients with HCV-related chronic liver
disease. Diabetol Metab Syndr. 5:512013. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
García-Monzón C, Lo Iacono O, Crespo J,
Romero-Gómez M, García-Samaniego J, Fernández-Bermejo M,
Domínguez-Díez A, de Rodríguez Cía J, Sáez A, Porrero JL, et al:
Increased soluble CD36 is linked to advanced steatosis in
nonalcoholic fatty liver disease. Eur J Clin Invest. 44:65–73.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Masuda Y, Tamura S, Matsuno K, Nagasawa A,
Hayasaka K, Shimizu C and Moriyama T: Diverse CD36 expression among
Japanese population: Defective CD36 mutations cause platelet and
monocyte CD36 reductions in not only deficient but also normal
phenotype subjects. Thromb Res. 135:951–957. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Ghosh A, Murugesan G, Chen K, Zhang L,
Wang Q, Febbraio M, Anselmo RM, Marchant K, Barnard J and
Silverstein RL: Platelet CD36 surface expression levels affect
functional responses to oxidized LDL and are associated with
inheritance of specific genetic polymorphisms. Blood.
117:6355–6366. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Alexander Aguilera A, Hernández Díaz G,
Lara Barcelata M, Angulo Guerrero O and Oliart Ros RM: Induction of
Cd36 expression elicited by fish oil PUFA in spontaneously
hypertensive rats. J Nutr Biochem. 17:760–765. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Griffin E, Re A, Hamel N, Fu C, Bush H,
McCaffrey T and Asch AS: A link between diabetes and
atherosclerosis: Glucose regulates expression of CD36 at the level
of translation. Nat Med. 7:840–846. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Tandon NN, Kralisz U and Jamieson GA:
Identification of glycoprotein IV (CD36) as a primary receptor for
platelet-collagen adhesion. J Biol Chem. 264:7576–7583.
1989.PubMed/NCBI
|
|
32
|
Knøsgaard L, Thomsen SB, Støckel M,
Vestergaard H and Handberg A: Circulating sCD36 is associated with
unhealthy fat distribution and elevated circulating triglycerides
in morbidly obese individuals. Nutr Diabetes. 4:e1142014.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Handberg A, Højlund K, Gastaldelli A,
Flyvbjerg A, Dekker JM, Petrie J, Piatti P and Beck-Nielsen H: RISC
Investigators: Plasma sCD36 is associated with markers of
atherosclerosis, insulin resistance and fatty liver in a
nondiabetic healthy population. J Intern Med. 271:294–304. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Alkhatatbeh MJ, Mhaidat NM, Enjeti AK,
Lincz LF and Thorne RF: The putative diabetic plasma marker,
soluble CD36, is non-cleaved, non-soluble and entirely associated
with microparticles. J Thromb Haemost. 9:844–851. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Chmielewski M, Bragfors-Helin AC,
Stenvinkel P, Lindholm B and Anderstam B: Serum soluble CD36,
assessed by a novel monoclonal antibody-based sandwich ELISA,
predicts cardiovascular mortality in dialysis patients. Clin Chim
Acta. 411:2079–1082. 2010. View Article : Google Scholar : PubMed/NCBI
|
